记者专访。 作为深耕生物科技领域的国际投行，今年以来，摩根士丹利保荐了恒瑞医药、映恩生物、维立志博等标志性港股IPO项目，并完成了药明康德9.8亿美元、信达生物 5.5亿美元、翰森制药约5亿美元等多个再融资项目。 近日，证券时报·券商中国记者专访了摩根士丹利亚太股权资本市场主管张晓羽、亚太医疗投资银行主管孙锶铭，从投行角度洞察中国创新药行业正在发生的巨变。 张晓羽认为，今年以来，国际投资者对中国生物科技企业的关注度持续升温。孙锶铭也表示，凭借创新、成本和政策优势，中国生物科技企业已成为全球市场的重 要参与者。 国际资本持续买入 据张晓羽介绍，近年来港交所已成为全球第二大生物科技融资中心。2025年上半年，港股市场有12家医疗健康企业成功上市，累计筹资25亿美元。其中，8家生物 科技公司依据港股第18A章（港交所为吸引创新生物科技企业而设的"绿色通道"）上市，筹资总额达8.9亿美元。值得一提的是，恒瑞医药5月23日登陆港交所，成为 2021年以来全球规模最大的医疗行业IPO项目，随后A、H股齐涨，而近期H股股价还较A股获得一定溢价，说明了国际投资者对公司的认可和持续追捧。 新上市企业市场表现亮眼，上述12家医疗 ...

作为深耕生物科技领域的国际投行，今年以来，摩根士丹利保荐了恒瑞医药、映恩生物、维立志博等标志性港股IPO 项目，并完成了药明康德9.8亿美元、信达生物5.5亿美元、翰森制药约5亿美元等多个再融资项目。 新上市企业市场表现亮眼，上述12家医疗公司上市首日平均涨幅达23.1%。 由摩根士丹利牵头保荐的映恩生物4月15日上 市首日暴涨117%，被普遍认为是重新打开中国生物科技企业港股上市的大门。全球投资者认购热情高涨，如由摩根士丹 利牵头保荐的维立志博，获得了长线、主权、医疗专业投资者的超额认购及支持。 再融资股本发行同样活跃。张晓羽介绍，截至7月底，摩根士丹利已协助中国业内发行人融资超50亿美元。其中，药明康 德7月底成功配售73.8万股H股，募资9.8亿美元（约76.47亿港元），为过去4年港股医疗行业最大新股增发项目。另外， 摩根士丹利也协助信达生物近期完成5.5亿美元（约43.1亿港元）增发，为过去4年港股医疗行业折扣最小的增发案例，因 市场需求远超预期，发行规模较原计划上调10%，发行折扣缩窄至4.9%。8月19日，翰森制药也宣布进行5亿美元（约39 亿港元）的增发，摩根士丹利助力其进行配售，该交易将于8 ...

Group 1 - China's innovative drug assets are increasingly recognized globally, capturing a larger share of the global innovative drug licensing market, with 27% of global transaction volume and 32% of transaction value in 2023 [1] - Despite the growth, only 10 out of 307 new drugs approved by the FDA since 2019 are from China, representing less than 3% [1][11] - The market capitalization of Chinese pharmaceutical and biotech companies is significantly lower than their US counterparts, with only 14% of the total market cap of US listed companies [7] Group 2 - The Hong Kong stock market has seen multiple "10x stocks" in the pharmaceutical sector, with companies like Deqi Medicine and Hengrui Medicine experiencing significant price increases [4][5] - The recent IPOs of biopharmaceutical companies in Hong Kong have nearly matched the total for 2023, indicating a strong market interest [5] - A wave of high-profile IPOs is expected in the second half of 2025, driven by improved market conditions and increased liquidity [5][6] Group 3 - The capital market's enthusiasm has led to significant refinancing activities among listed companies, with major transactions from companies like Innovent Biologics and I-Mab [6] - Chinese companies now account for about one-third of the global pipeline of innovative drugs, with a total transaction scale of $48 billion in the first half of 2025 [6] - The trend of increasing licensing agreements with multinational pharmaceutical companies is expected to continue, as many innovative drugs are entering clinical stages [9][10] Group 4 - The focus of Chinese innovative drugs remains on oncology, with over 60% of licensing transactions in the past three years related to cancer treatments [12] - There is a rising interest in cardiovascular and metabolic disease drugs, particularly GLP-1 medications, which are becoming a focal point for multinational companies [12][13] - The global valuation of innovative drugs is undergoing a transformation, with a cautious approach towards high-priced acquisitions of late-stage drugs [10]

Group 1: Industry Overview - Major multinational pharmaceutical companies (MNCs) have reported their performance for the first half of 2025, with Johnson & Johnson leading with revenues of $45.636 billion, followed by Roche and Merck [1][2] - Nearly 200 drugs are expected to lose patent protection in the coming years, including at least 69 blockbuster drugs with annual sales exceeding $1 billion, leading to an estimated cumulative sales loss of over $300 billion for MNCs [2][3] - The competitive landscape among the top ten pharmaceutical companies remains intense, with close revenue figures among companies ranked fourth to eighth [2] Group 2: Company Performances - Johnson & Johnson reported a revenue of $45.636 billion for the first half of 2025, a year-on-year increase of 4.1%, driven by its innovative pharmaceuticals and medical technology segments [3] - Merck's total revenue was $31.335 billion, a decline of 2% year-on-year, with significant drops in its China revenue, which fell by 70% to $1.075 billion [4] - Eli Lilly achieved a remarkable revenue growth of 41%, reaching $28.286 billion, with its weight loss drug Mounjaro seeing an 85% increase in sales [5][6] - AstraZeneca reported a revenue of $28.045 billion, an 11% increase, with its China revenue growing by 5% to $3.515 billion, making it the top performer in the Chinese market [7] Group 3: Market Dynamics - The competition for the title of "King of Drugs" is intensifying, with Eli Lilly's two weight loss drugs nearing the sales figures of Novo Nordisk's semaglutide [6] - MNCs are increasingly focusing on the Chinese market, with a notable increase in collaborations with domestic innovative pharmaceutical companies, resulting in 52 outbound deals in the first half of 2025 [7][8] - The growth rates of MNCs in China are shifting, with some companies like Merck experiencing significant declines in sales, while others like AstraZeneca and Eli Lilly are capitalizing on the market opportunities [8]

Core Viewpoint - Novo Nordisk reported strong financial results for the first half of the year, driven by robust performance in the obesity treatment sector, despite a downward revision of revenue and operating profit expectations for 2025 due to anticipated market slowdowns and increased competition [4][8]. Financial Performance - For the first half of 2023, Novo Nordisk achieved sales of 154.9 billion Danish Krone (approximately 22.3 billion USD, 160.2 billion RMB), representing an 18% year-over-year growth at constant exchange rates [4]. - Operating profit reached 72.2 billion Danish Krone (approximately 10.4 billion USD, 74.7 billion RMB), marking a 29% increase compared to the previous year [4]. - The obesity treatment segment saw sales growth of 56%, significantly contributing to overall revenue [4]. Business Segment Analysis - The diabetes and obesity care division generated sales of 145.4 billion Danish Krone (approximately 21.5 billion USD), with an 18% year-over-year increase [4]. - Revenue from obesity drugs surged by 58% to 38.8 billion Danish Krone (approximately 5.7 billion USD) [4]. Product Performance - Sales of the diabetes drug Ozempic reached 64.5 billion Danish Krone (approximately 9.6 billion USD), a 15% increase year-over-year [6]. - Rybelsus, the oral formulation of semaglutide, generated sales of 11.3 billion Danish Krone (approximately 1.7 billion USD), reflecting a 5% growth [6]. - Wegovy, the weight loss injection, achieved sales of 36.9 billion Danish Krone (approximately 5.4 billion USD), with a remarkable 78% increase [6]. Market Position and Competition - Semaglutide's sales have surpassed that of the previously leading drug, Pembrolizumab (Keytruda), which recorded global sales of 15.2 billion USD in the first half of 2023, growing only 7% [8]. - The company has adjusted its 2025 revenue and profit forecasts due to anticipated slower growth in the U.S. obesity market and increased competition in the GLP-1 diabetes market [8]. Regulatory and Market Challenges - Despite the end of the FDA's grace period for large-scale compounding of drugs, illegal compounding practices continue, posing risks to patients [10]. - Novo Nordisk is taking legal action to protect patients from counterfeit semaglutide products and is advocating for stronger regulatory measures [10]. - The company's NovoCare pharmacy and telehealth initiatives are aimed at improving patient access, although current penetration rates are below expectations due to market expansion slowdowns and competition [10].

Group 1 - In 2024, China approved 48 innovative drugs, more than five times the number in 2018, with nearly 40 approved in the first half of the year, indicating a significant "explosion effect" in the sector [1] - The number of innovative drugs approved by the U.S. FDA in 2024 is 50, only two more than China's total, suggesting that China may surpass developed countries in high-tech innovation in the pharmaceutical field [1] - The approval of innovative drugs in China is particularly focused on oncology, with lung cancer being a major health threat, leading to advancements in drug development that enhance treatment options and patient survival rates [1] Group 2 - Bispecific antibodies and antibody-drug conjugates are at the forefront of innovative oncology drugs, with only four bispecific drugs approved globally, one of which is China's innovative drug, Ivosidenib [2] - A head-to-head clinical trial published in The Lancet showed that Ivosidenib significantly outperformed the well-known cancer drug Pembrolizumab in terms of progression-free survival [2] - The first international phase III clinical study of Ivosidenib has concluded enrollment and is awaiting FDA review for lung cancer indications [2] Group 3 - The innovative drug Lurbinectedin was approved in March 2024, becoming the first antibody-drug conjugate for lung cancer indications globally, marking a shift from "catching up" to "leading" in drug development [3] - The rapid development of innovative drugs in China is attributed to supportive policies, including the recently approved "Implementation Plan for Supporting Innovative Drug Development" by the State Council [3] - Ivosidenib was approved in May 2024 and included in the medical insurance list the same year, allowing patients to benefit from insurance reimbursement starting January 1, 2025 [3] Group 4 - Among the 91 drugs newly included in the medical insurance directory in 2024, 33 were approved and included in the same year, reducing the time from approval to insurance coverage from about five years to one year [4] - The price of Ivosidenib dropped by 68% after being included in the insurance directory, significantly alleviating the financial burden on patients [4] - The five-year survival rate for cancer patients in China has improved from 33.3% a decade ago to 43.7% by the end of 2023, translating to an additional 500,000 lives saved each year [5] Group 5 - Despite rapid development, the Chinese innovative drug market faces challenges such as homogenization and lack of clear clinical advantages, leading to "involution" in competition [6] - The National Medical Insurance Administration emphasizes the need to support true innovation and differentiated innovation to guide the development of the biopharmaceutical industry [6] - New measures have been introduced to utilize medical insurance data for innovative drug research and development, enhancing the efficiency of innovation [7] Group 6 - A new commercial health insurance directory for innovative drugs has been established, allowing for the inclusion of high-value drugs that exceed basic insurance coverage [8] - The commercial health insurance sector in China is growing, with a premium income of 977.3 billion yuan in 2024, indicating a potential for increased support for innovative drugs [9] - The establishment of the commercial health insurance directory aims to alleviate the financial burden on patients while ensuring sustainable development for innovative drug companies [10] Group 7 - Companies can apply for inclusion in both the medical insurance directory and the commercial health insurance directory, with the latter allowing for greater involvement of insurance companies in the decision-making process [11]

Core Viewpoint - The rapid advancement of China's biotechnology sector is comparable to its breakthroughs in artificial intelligence and electric vehicles, with Chinese pharmaceutical companies now challenging Western dominance in innovation [1][2]. Group 1: Growth in Drug Development - In the past year, over 1250 new drugs entered the research and development phase in China, significantly surpassing the EU and nearing the US's 1440 new drugs [1]. - China's contribution to global innovative drug development has increased from 160 compounds in 2015 to nearly equal levels with the US, indicating a strong growth trajectory [2]. - The number of innovative drugs entering the R&D pipeline in China is expected to surpass that of the US in the coming years [2]. Group 2: Quality of Innovation - Chinese biotech innovation quality has improved, gaining recognition from global regulatory bodies like the FDA and EMA, which are now prioritizing the review of Chinese drugs [5]. - As of 2024, China has slightly outpaced the EU in obtaining fast-track review qualifications for new drugs, enhancing its competitive edge [5]. - A notable example of innovation is a cell therapy developed by Legend Biotech, which has received multiple fast-track designations and is considered superior to a similar US therapy [5]. Group 3: Market Dynamics and Acquisitions - Major pharmaceutical companies are increasingly acquiring Chinese biotech firms, indicating a shift in the competitive landscape towards China [6][9]. - Akeso's new cancer drug has shown higher efficacy than Merck's Keytruda, attracting significant global attention and leading to record acquisition deals [9]. - The frequency and value of transactions involving Chinese drug candidates are rising, reflecting confidence in their international competitiveness [9]. Group 4: Cost and Efficiency Advantages - Chinese biotech companies can conduct research at lower costs and faster speeds across all R&D stages, aided by a large patient base and centralized hospital networks [11]. - The efficiency of Chinese doctors in patient recruitment for clinical trials is notably higher, taking only half the time compared to their US counterparts [11]. - Since 2021, China has become the preferred location for clinical trials, initiating the highest number of new studies globally [13]. Group 5: Future Outlook and Geopolitical Context - The rapid development of China's biotech ecosystem raises concerns among US policymakers about losing leadership in a critical industry [14][15]. - The US government is responding by tightening controls on scientific equipment exports and promoting domestic biotech growth [15]. - Despite geopolitical tensions, Chinese companies are focused on expanding into developed Western markets to benefit global patients [15].

Core Viewpoint - The investigation into the use of clinical research anti-cancer drugs by two patients in Chongqing highlights issues related to medical recommendations, drug procurement, and regulatory compliance in the healthcare sector [1][2][3]. Group 1: Patient Cases - Patient Li was diagnosed with cervical cancer in June 2013 and underwent surgery, later receiving treatment at Chongqing University Cancer Hospital, where she was recommended to use the drug Cadonilimab starting April 17, 2024 [2]. - Patient Tang was diagnosed with cervical cancer in June 2017 and was also recommended to use Cadonilimab after a recurrence in January 2024, starting her treatment on January 30, 2024 [2][4]. Group 2: Medical Professional Conduct - The investigation revealed that the doctor, referred to as Li, recommended Cadonilimab to both patients, despite the initial recommendation for a different drug, Pembrolizumab, citing cost and effectiveness [4][5]. - Doctor Li admitted to discussing potential risks associated with Cadonilimab, which has a reported incidence of immune-related pneumonia at 1.7% [3][4]. Group 3: Drug Procurement and Usage - Cadonilimab was approved for sale on June 28, 2022, with a market price of 13,220 yuan per unit, and patients could obtain it through various means, including self-purchase and charity programs [6][7]. - Both patients acquired a total of 70 and 90 units of Cadonilimab, respectively, through a combination of self-purchase, charity donations, and clinical research supplies [6][7]. Group 4: Regulatory and Compliance Issues - The investigation found that the clinical research drugs obtained by the patients were improperly sourced, with evidence of forged documents used to acquire these drugs from pharmacies [8][9]. - The pharmacies involved were penalized for non-compliance with drug management regulations, highlighting systemic issues in the oversight of drug distribution [9]. Group 5: Quality and Safety of the Drug - The investigation confirmed that the Cadonilimab used by the patients was produced according to national standards and did not exhibit quality issues, despite being labeled for clinical research use [10][11]. Group 6: Institutional Response - Following the investigation, health authorities initiated a comprehensive review of medical practices and regulatory compliance to prevent similar incidents in the future, emphasizing the need for improved oversight in clinical research and drug management [12].

Core Viewpoint The article discusses the investigation into the use of clinical research anti-cancer drugs by two patients in Chongqing, highlighting the actions of medical professionals and the procurement of the drugs, as well as the regulatory implications. Group 1: Basic Situation - Patient Li was diagnosed with cervical cancer in June 2013 and underwent surgery, later receiving treatment at Chongqing University Cancer Hospital. In August 2023, her condition recurred, leading to the recommendation of the drug Cadonilimab by her doctor [2] - Patient Tang was diagnosed with cervical cancer in June 2017 and also underwent surgery. In January 2024, her condition recurred, and she was recommended to use Cadonilimab as a more affordable option compared to another drug [2] Group 2: Investigation and Handling - The investigation revealed that Doctor Li recommended Cadonilimab to both patients, which was confirmed through patient interviews and communication records [3][4] - Doctor Li acknowledged the recommendation of Cadonilimab and admitted to providing patients with information about the drug's effects and risks [5][6] Group 3: Drug Procurement - Cadonilimab was approved for sale in June 2022 at a price of 13,220 yuan per unit. Patients could obtain it through self-purchase, charity programs, or clinical research projects [7] - Patient Li obtained a total of 70 units of the drug through various means, while Patient Tang obtained 90 units, with both patients having purchased some units at the market price [8] Group 4: Clinical Research Drug Sources - The investigation found that the clinical research drugs obtained by the patients were improperly sourced, with evidence of forgery by sales personnel from the drug company [9] - The pharmacies involved were found to have violated regulations by distributing clinical research drugs without proper authorization [10] Group 5: Drug Quality Verification - Cadonilimab was confirmed to meet quality standards as it was approved by the National Medical Products Administration, and the drugs used by the patients were produced according to regulatory requirements [11][12] Group 6: Investigation of Clinics - The clinic where the patients received infusions was found to have legitimate qualifications but was involved in irregularities, including the use of forged prescriptions [13]

Core Viewpoint - The investigation into the use of clinical research anti-cancer drugs by two patients in Chongqing has revealed significant issues regarding the recommendation and procurement of these medications, highlighting potential violations of medical ethics and regulations [1][5]. Group 1: Patient Cases - Patient Li was diagnosed with cervical cancer in June 2013 and underwent surgery, later receiving treatment at Chongqing University Cancer Hospital, where she was recommended to use the drug Cadonilimab after a positive PD-L1 test in August 2023 [2]. - Patient Tang was diagnosed with cervical cancer in June 2017 and, after a recurrence, was recommended to use Cadonilimab instead of the initially suggested Pembrolizumab due to cost considerations [2][4]. Group 2: Medical Professional Conduct - The investigation found that the doctor involved, referred to as Li, recommended Cadonilimab to both patients, which is within the scope of normal medical practice according to clinical guidelines [5]. - However, the doctor violated local regulations by recommending a sales representative to the patients, leading to disciplinary actions including warnings and suspension of prescription rights [5]. Group 3: Drug Procurement and Usage - Cadonilimab was approved for market sale on June 28, 2022, with a price of 13,220 yuan per unit, and patients could obtain it through various means, including self-purchase and charity programs [6][7]. - Both patients acquired a total of 70 and 90 units of the drug respectively, with a significant portion obtained through clinical research channels, raising concerns about the legitimacy of these sources [7]. Group 4: Clinical Research Drug Sources - The investigation revealed that the clinical research drugs obtained by the patients were marked as "for clinical research use" and were not part of any approved clinical trials at the hospitals involved [8][10]. - Sales personnel from the drug company were found to have forged documents to obtain these drugs, leading to regulatory scrutiny and potential legal consequences [8][9]. Group 5: Quality and Compliance of Drugs - The drugs used by the patients were confirmed to meet national quality standards, despite being labeled for clinical research, indicating compliance with production regulations [10][11]. - The investigation prompted a review of the management of clinical research drugs and the implementation of stricter regulations to prevent future violations [12].